Disc Col

loading

Use of proton pump inhibitors and risk of osteoporosis-related fractures.[CMAJ. 2008]
Use of proton pump inhibitors and risk of osteoporosis-related fractures.
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. CMAJ. 2008 Aug 12; 179(4):319-26.
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.[Pharmacotherapy. 2008]
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA, Jick H. Pharmacotherapy. 2008 Aug; 28(8):951-9.
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.[Ann Epidemiol. 2014]
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Ann Epidemiol. 2014 Apr; 24(4):286-90. Epub 2014 Jan 16.
Review Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.[Eur J Gastroenterol Hepatol. 2...]
Review Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.
Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J. Eur J Gastroenterol Hepatol. 2011 Sep; 23(9):794-800.
Review Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.[Am J Gastroenterol. 2008]
Review Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.
Moayyedi P, Cranney A. Am J Gastroenterol. 2008 Oct; 103(10):2428-31.

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.[Sci Rep. 2017]
Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.
Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, Liu H, Amin S. Sci Rep. 2017 Jul 17; 7(1):5527. Epub 2017 Jul 17.
A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.[Clin Transl Sci. 2017]
A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.
Dubcenco E, Beers-Block PM, Kim LP, Schotland P, Levine JG, McCloskey CA, Bashaw ED. Clin Transl Sci. 2017 Sep; 10(5):387-394. Epub 2017 Jun 15.
Acid-suppressive medications and risk of fracture: an updated meta-analysis.[Int J Clin Exp Med. 2015]
Acid-suppressive medications and risk of fracture: an updated meta-analysis.
Cai D, Feng W, Jiang Q. Int J Clin Exp Med. 2015; 8(6):8893-904. Epub 2015 Jun 15.

Your browsing activity is empty.

Activity recording is turned off.